Nicoletta Bernardini
Overview
Explore the profile of Nicoletta Bernardini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Iuliano M, Grimaldi L, Rosa P, Scibetta S, Bernardini N, Proietti I, et al.
Front Immunol
. 2024 Jun;
15:1360618.
PMID: 38827737
Psoriasis is a chronic inflammatory disease affecting skin and joints characterized by a chronically altered immune and inflammatory response. Several factors occur from the onset to the development of this...
12.
Bernardini N, Dattola A, Caldarola G, Orsini D, Assorgi C, DAmore A, et al.
Drugs Context
. 2024 May;
13.
PMID: 38817804
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant...
13.
Caldarola G, Galluzzo M, Bernardini N, Botti E, De Luca E, De Simone C, et al.
Dermatol Pract Concept
. 2024 May;
14(2).
PMID: 38810071
Introduction: Data about the long-term effectiveness of brodalumab could be valuable in assessing patient adherence to treatment and improving psoriasis management. Objective: The aim of our study was to evaluate...
14.
Alulis S, Bernardini N, Burlando M, Costanzo A, Francesa Morel P, Gisondi P, et al.
Dermatol Ther (Heidelb)
. 2024 May;
14(5):1273-1291.
PMID: 38727995
Introduction: There are several treatment options for plaque psoriasis (PsO), but uncertainty remains around the optimal sequencing of treatments. The aims of this study were to investigate how adopting a...
15.
Caldarola G, Pinto L, Bellinato F, Bernardini N, Campione E, Chiricozzi A, et al.
Expert Opin Drug Saf
. 2024 May;
23(11):1483-1487.
PMID: 38717372
Background: Alopecia areata (AA) is a non-scarring disorder characterized by hair loss that greatly affects patients' quality of life and has a chronic, recurring course. This disease is marked by...
16.
Bernardini N, Ambrosio L, Tolino E, Proietti I, Skroza N, Potenza C
J Clin Med
. 2024 Apr;
13(8).
PMID: 38673523
: Treating psoriasis patients requires the consideration of potential underlying complications like latent viral infections and chronic kidney disease, which may influence therapy selection. : A patient with end-stage kidney...
17.
Proietti I, Battilotti C, Svara F, Tolino E, Bernardini N, Skroza N, et al.
Case Rep Oncol Med
. 2024 Apr;
2024:5559093.
PMID: 38572350
The use of hyaluronic acid (HA) fillers in oncology patients undergoing PET-CT scans is a topic of debate due to potential interference with imaging accuracy. A 54-year-old female, postmelanoma metastasectomy...
18.
Proietti I, Svara F, Battilotti C, Tolino E, Bernardini N, Skroza N, et al.
J Cosmet Dermatol
. 2024 Mar;
23(6):2304-2306.
PMID: 38456485
No abstract available.
19.
Orsini D, Caldarola G, Dattola A, Campione E, Bernardini N, Frascione P, et al.
J Dermatolog Treat
. 2024 Feb;
35(1):2319304.
PMID: 38413097
Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in...
20.
Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, et al.
Clin Cosmet Investig Dermatol
. 2023 Dec;
16:3561-3574.
PMID: 38107670
Purpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study...